Page 22 - Zyme Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

    Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that its Annual Report and Accounts for the year ended 31 December 2020 and the Notice of the 2021 Annual General Meeting are now available on the Company's website, www.avacta.com. Copies of the Annual Report and Accounts and the Notice of AGM have been posted to shareholders who have elected to receive them in paper form.   The Annual General Meeting will be held on...

First-in-human clinical study for Acute Myeloid Leukaemia expected to begin later in 2021 FDA also granted orphan drug designation to GDX012 for the treatment of Acute Myeloid Leukaemia GammaDelta

ERS Genomics Limited: ERS Genomics and GenScript Biotech Corporation sign CRISPR/Cas9 license agreement License agreement to enhance GenScript's CRISPR offering for gene and cell therapy research ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and GenScript Biotech Corporation (GenScript), the world's leading research reagent provider, today announced a non-exclusive license agreement granting GenScript access to ERS Genomics' CRISPR/Cas9 patent portfolio. GenScript is a global biotech...

More from AP

More from AP